Search PubMed⌕ Search

Biomedical subjects

P D Fowler

Publications and source records attributed to P D Fowler.

At least 55 records · Page 3Linked to original sources
PubMed1979

A double-blind comparison of diclofenac sodium (Voltarol) and placebo in inpatients with rheumatoid arthritis.

This preliminary study compared placebo with diclofenac (50 mg, rising to 150 mg per day) in a crossover study for seven days in thirteen inpatients. Regardless of the marked overall effect of hospitalization, an additional effect of diclofenac on grip strength and p.i.p. joint swelling was demonstrated, as well as a significant reduction in pain and in analgesic requirements. In addition, an improved technique for assessing the effect of NSAI drugs on p.i.p. joint swelling is described.

Arthritis, Rheumatoid↗
PubMed1979

Diclofenac (Voltarol) in rheumatoid arthritis: a report of a double-blind trial.

A double-blind trial compared diclofenac with placebo in 44 outpatients. On from each group dropped out with dyspepsia, and one (placebo group) with ineffective treatment. Twenty completers received diclofenac. Dosage was one tablet (25 mg diclofenac) three times daily during the first week. In the second (final) week, most patients had four or six tablets. Diclofenac had significantly greater effect on pain, grip, morning stiffness, joint tenderness and swelling, and in comparison to previous treatments, even though the placebo group required significantly more rescue anaglesic. A few patients in each group had slight dyspepsia. One in the active and six in the placebo group complained of minor central nervous system symptoms. There were no serious side-effects. Haematological, biochemical and urinary analyses showed no clinically important changes. It is concluded that, in the short term, diclofenac (Voltarol) is effective in relieving the symptoms of inflammatory polyarthritis. It is well tolerated as placebo medication, and had no detrimental haematological or biochemical effects.

Arthritis, Rheumatoid↗
PubMed1979

Diclofenac sodium (Voltarol): a double-blind comparative study with ibuprofen in patients with rheumatoid arthritis.

A double-blind comparative trial in 60 patients, using diclofenac (Voltarol) and ibuprofen (Brufen), showed a considerable improvement in morning stiffness amongst females in the diclofenac group. However, no significant differences was noted between these two drugs in relation to pain score, articular index or proximal interphalangeal joint size. Analysis of withdrawals and side-effects suggests that while ibuprofen may be slightly better tolerated, it is also associated with significantly more withdrawals due to lack of effect. No significant change in laboratory studies was noted, except for a slight decrease in mean haemoglobin levels. The trialist noted that all of the drop-outs and side-effects reported came from one hospital out of the four participating; this was possibly due to differences in pre-trial drug therapy and to the hospital being in an urban, rather a rural, situation.

Adult↗
PubMed1977

Drug and non-drug factors influencing adverse reaction to pyrazoles.

Some of the factors influencing the likelihood of the appearance of adverse drug reactions in patients are identified and discussed. Ways of quantifying some of the risks of adverse reactions in different patients are demonstrated. It is pointed out that adverse reaction data can give valuable guidance for both day-to-day patient management and for the initiation or guidance of research projects. In this latter connection, this study highlights the difference in time of onset between aplastic anaemia and agranulocytosis, suggesting different mechanisms of reaction. The majority of adverse reactions occur during the first three weeks of treatment and it is during this time that patients must be most carefully supervised. The old patients should be watched with particular care. It is concluded that age, sex, disease being treated, length of treatment and even the geographical location where the patient lives, can affect the time, type, frequency and outcome of an adverse drug reaction.

Adult↗
PubMed1977

Butacote: the first assessment in general practice.

A double-blind crossover trial in the treatment of rheumatic conditions in general practice compared the effect and tolerance of 100 mg t.d.s. standard phenylbutazone (Butazolidine) with enteric-coated phenylbutazone (Butacote), each preparation being given for one week to fifty patients. There was no difference in effectiveness. Nine patients complained of dyspeptic symptoms, three during the first week, six during the second week, but none during treatment with Butacote. This, together with the significant 17:7 patient preference, clearly demonstrated the superiority of Butacote.

Clinical Trials as Topic↗
PubMed1977

Juvenile chronic polyarthritis: clinical sub-groups and response to medication.

Juvenile ankylosing spondylitis, as a clinical entity, is outlined. A double-blind trial compared Safapryn and Butazolidin, each given for 3 months, for 15 treatment periods in 11 patients. No differences were shown, but the study highlighted the problems of assessing this condition, and some comments are made, hopefully, to guide further investigators in this field.

Acetaminophen↗
PubMed1975

Phenylbutazone and hepatitis.

During a comparative trial between enteric-coated and rectally administered phenylbutazone in patients with rheumatoid disease, one patient developed a mild hepatitis. She had recently concluded a long period of gold therapy. The natural history of phenylbutazone hepatitis is reviewed on the basis of 41 case histories, and the experience with this individual patient interpreted accordingly.

Aged↗
PubMed1972

A study of clofazimine in the rat.

1. Clofazimine, an anti-mycobacterial agent used in the treatment of leprosy, has been reported to be particularly effective in the treatment of acute erythema nodosum leprosum reactions.2. The present experiments were designed to study in the rat this apparent anti-inflammatory activity.3. In doses relatively non-toxic to the animals clofazimine inhibited both rat adjuvant arthritis and the inflammatory paw swelling following an adjuvant injection.4. Clofamizine failed to inhibit both the primary antibody response to sheep erythrocytes and the tuberculin skin response.5. It is concluded that clofazimine exhibits definite anti-inflammatory (but not immunosuppressive) activity, and that it should be tested in patients with rheumatoid arthritis.

Adjuvants, Immunologic↗